Oncoinvent ASA: Promising Update from Phase 1 Ovarian Cancer Trial

In a significant development for the radiopharmaceutical sector, Oncoinvent ASA, a clinical-stage company listed on the Frankfurt Stock Exchange, has announced encouraging results from its Phase 1 clinical trial involving Radspherin®. The trial, which focused on patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis, has shown no new recurrences over an 18-month follow-up period. This promising outcome underscores the potential of Radspherin® in preventing disease progression, a critical milestone for Oncoinvent’s innovative treatment approach.

The trial, identified as RAD-18-001, concluded its recruitment phase at the end of 2023. It involved 10 patients who received a single intraperitoneal dose of 7 MBq Radspherin®. The absence of new recurrences among these patients highlights the continued promise of Radspherin® as a viable treatment option for metastatic cancers in body cavities, particularly within the Norwegian patient population that Oncoinvent serves.

Financial and Corporate Developments

In addition to the clinical trial updates, Oncoinvent ASA has extended an invitation to a presentation of its Q1 2025 company update. This event is anticipated to provide further insights into the company’s financial health and strategic direction. As of April 24, 2025, Oncoinvent’s share price stood at 0.1306 EUR, with a market capitalization of approximately 11.96 million EUR. The company’s financial calendar, which outlines key dates and events, will be crucial for investors and stakeholders looking to understand Oncoinvent’s trajectory in the coming months.

Market Context and Outlook

Oncoinvent ASA’s recent developments come at a time when the radiopharmaceutical industry is under intense scrutiny for its potential to offer targeted cancer treatments. The company’s focus on developing radioactive micro particle suspensions for the local treatment of metastatic cancers positions it uniquely within the market. The positive results from the Phase 1 trial not only bolster Oncoinvent’s clinical portfolio but also enhance its appeal to investors and partners in the healthcare sector.

As Oncoinvent prepares to share more detailed financial and operational updates in its upcoming presentation, the market will be keenly watching for indications of how the company plans to leverage its recent clinical successes. With a robust pipeline and a clear focus on addressing unmet needs in cancer treatment, Oncoinvent ASA is poised to make significant strides in the radiopharmaceutical landscape.

In conclusion, Oncoinvent ASA’s announcement of the 18-month follow-up results from its Phase 1 ovarian cancer trial marks a pivotal moment for the company. The continued promise of Radspherin® in preventing disease progression, coupled with the company’s strategic financial planning, sets a positive tone for Oncoinvent’s future endeavors in the fight against cancer.